论文部分内容阅读
目的:探讨恶性胸腔积液腔内注入不同药物与疗效及不良反应的关系。方法:将119例经病理细胞学确诊为恶性胸腔积液病人随机分成3组,A组(卡铂组)46例,B组(白细胞介素-2组)32例,C组(胞必佳组)41例,排净胸液后分别注入不同药物。结果:A、B、C组总有效率分别为80.4%、71.9%、73.2%,无显著性差异(P>0.05),完全缓解率分别为34.8%、9.4%、9.8%,有显著性差异(P<0.01)。不良反应A组主要为轻度骨髓抑制及恶心呕吐,发生率在8.7%-10.9%;B组表现为寒颤、发热、胸痛,发生率在15.6%-71.8%;C组除寒颤、发热、胸痛发生率较高在36.7%-95.1%外,还有14.6%出现气促发绀,8.7%出现Ⅰ型呼吸衰竭。显示在对病人体质及生活质量影响较明显的不良反应中,A组分别与B组、C组比较均有显著差异(P<0.05)。结论:卡铂胸腔内介入化疗治疗恶性胸腔积液是一个疗效高、不良反应少的方法。
Objective: To investigate the relationship between different drugs injected into malignant pleural effusion cavity and curative effect and adverse reaction. Methods: A total of 119 patients with pathologically confirmed cytological malignant pleural effusion were randomly divided into 3 groups: 46 patients in group A (carboplatin group), 32 patients in group B (interleukin-2 group), 32 patients in group C Group) 41 cases, after discharging the pleural fluid were injected with different drugs. Results: The total effective rates in group A, B and C were 80.4%, 71.9% and 73.2% respectively, with no significant difference (P> 0.05). The complete response rates were 34.8%, 9.4% and 9.8% respectively, with significant difference (P <0.01). Adverse reactions in group A were mainly mild myelosuppression and nausea and vomiting, the incidence rate was 8.7% -10.9%; group B was shivering, fever, chest pain, the incidence was 15.6% -71.8%; C group in addition to chills, fever, chest pain A higher incidence of 36.7% -95.1% in addition, there are 14.6% appear to promote cyanotic cyanotic, 8.7% type Ⅰ respiratory failure. The results showed that there were significant differences (P <0.05) between group A and group B and group C, respectively, in adverse reactions that had a significant effect on the patient’s physique and quality of life. Conclusions: Carboplatin chemotherapy in the treatment of malignant pleural effusion is a high efficacy, less adverse reactions.